SUPN - Supernus Pharmaceuticals Inc Stock Price, Fair Value and News

$36.37+0.55 (+1.54%)

Delayed as of 22 Nov 2024, 11:58 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SUPN Price Action

Last 7 days

-1.0%

Last 30 days

6.2%

Last 90 days

2.4%

Trailing 12 Months

30.6%

SUPN RSI Chart

SUPN Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

46.47

Price/Sales (Trailing)

3.08

EV/EBITDA

11.81

Price/Free Cashflow

12.15

SUPN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SUPN Fundamentals

SUPN Revenue

Revenue (TTM)

641.5M

Rev. Growth (Yr)

14.17%

Rev. Growth (Qtr)

4.37%

SUPN Earnings

Earnings (TTM)

42.6M

Earnings Growth (Yr)

340.97%

Earnings Growth (Qtr)

93.3%

SUPN Profitability

EBT Margin

12.68%

Return on Equity

4.23%

Return on Assets

3.17%

Free Cashflow Yield

8.23%

SUPN Investor Care

Shares Dilution (1Y)

1.07%

Diluted EPS (TTM)

0.76

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	586.9M	601.4M	641.5M	0
2023	668.5M	634.0M	610.5M	0
2022	601.3M	630.1M	659.0M	667.2M
2021	556.4M	571.0M	564.3M	579.8M
2020	402.3M	424.3M	477.3M	520.4M
2019	403.9M	409.1M	408.2M	392.8M
2018	335.1M	358.8M	381.4M	408.9M
2017	228.4M	252.6M	276.2M	302.2M
2016	162.9M	178.9M	196.3M	215.0M
2015	112.3M	118.3M	135.0M	147.5M
2014	21.0M	50.3M	71.8M	92.7M
2013	1.4M	1.6M	2.8M	12.0M
2012	679.3K	555.7K	432.0K	1.5M
2011	0	25.6M	13.2M	803.0K
2009	0	0	0	37.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a product candidate in Phase II clinical trials for treating resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

CEO	Mr. Jack A. Khattar
WEBSITE	supernus.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	612

Supernus Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Supernus Pharmaceuticals Inc? What does SUPN stand for in stocks?

SUPN is the stock ticker symbol of Supernus Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Supernus Pharmaceuticals Inc (SUPN)?

As of Thu Nov 21 2024, market cap of Supernus Pharmaceuticals Inc is 1.98 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SUPN stock?

You can check SUPN's fair value in chart for subscribers.

Is Supernus Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether SUPN is over valued or under valued. Whether Supernus Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Supernus Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SUPN.

What is Supernus Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Nov 21 2024, SUPN's PE ratio (Price to Earnings) is 46.47 and Price to Sales (PS) ratio is 3.08. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SUPN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Supernus Pharmaceuticals Inc's stock?

In the past 10 years, Supernus Pharmaceuticals Inc has provided 0.149 (multiply by 100 for percentage) rate of return.